CHARLES F LEVENBACK to Dose-Response Relationship, Drug
This is a "connection" page, showing publications CHARLES F LEVENBACK has written about Dose-Response Relationship, Drug.
Connection Strength
0.087
-
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
Score: 0.035
-
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010 Mar 11; 3:9.
Score: 0.012
-
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71.
Score: 0.010
-
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003 Jan 15; 21(2):291-7.
Score: 0.007
-
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol. 2001 Sep; 82(3):420-6.
Score: 0.007
-
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300.
Score: 0.006
-
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996 May; 14(5):1552-7.
Score: 0.005
-
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy. Gynecol Oncol. 1995 Apr; 57(1):72-8.
Score: 0.004